DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Cutaneous T-cell lymphoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCutaneous T-cell lymphoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cutaneous t-cell lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
histone deacetylase 2 (HDAC2) — HDAC2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7ZZP · 1.52 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provide no clinical trial results for any specific drug in cutaneous T-cell lymphoma. The 1997 consensus conference report reviews epidemiology, pathology, and immunology, and identifies areas needing clinical research, but gives no numerical outcomes. The 2000 pathogenesis paper states the precise mechanisms of lymphomagenesis are still obscure, mentioning environmental factors, translocations, mutations, and genetic instability, but offers no treatment data. The 2006 overview notes that several clinical trials of targeted therapies have shown encouraging results, but provides no concrete response rates, survival figures, or sample sizes. The 2012 case report on CD8-positive primary cutaneous peripheral T-cell lymphoma, unspecified, describes a rare and heterogeneous group with a minority showing a CD8+ phenotype, but again supplies no efficacy numbers.
No drug is named in any abstract, and no claim of efficacy can be made from these texts. The 2006 paper’s mention of “encouraging results” is vague and unsupported by the data given. The 1997 consensus explicitly calls for more clinical research, indicating that even at that point, standard approaches were not settled. The 2000 paper’s admission that mechanisms are “still obscure” underscores the lack of a clear molecular target for most cases.
What is still missing is any completed, controlled trial that reports response rates or survival in a defined patient population. The abstracts do not describe a trial design, a patient stratification strategy, or a funding source for such work. Without these, the field remains at the stage of identifying possible targets rather than validating treatments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Seminars in Cutaneous Medicine and Surgery · 2000 · 44 citations
Pathogenesis of cutaneous lymphomas
AbstractCutaneous lymphomas are a heterogeneous group of lymphoproliferative disorders derived from T cells, B cells and, in rare cases, natural killer cells. The precise mechanisms of the lymphomagenesis are still obscure. However, there are various factors involved. These factors include environmental, especially infectious factors, translocations, mutations and genetic instability. The special microenvironment in the skin is responsible for the peculiar behavior of these neoplasms by providing various key factors, such as adhesion molecules and cytokines. Newly identified molecular disturbances in cutaneous lymphomas might be targeted by specific molecular or immunologic interventions in the future.
Journal of the American Academy of Dermatology · 1997 · 25 citations · open access
Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations
AbstractAt the International Consensus Conference for Cutaneous T-Cell Lymphoma (CTCL) Treatment Recommendations (held in Boston, Massachusetts, Oct. 1 and 2, 1994), international experts were asked to assess where consensus existed and to identify areas that required clinical research. We review the epidemiology, pathology, and immunology of CTCL, summarize the important areas in which consensus exists, and discuss newer targeted therapies.
JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2006 · 21 citations
New insights into the molecular biology and targeted therapy of cutaneous T‐cell lymphomas
AbstractCutaneous T-cell lymphoma is an extra-nodal non-Hodgkin lymphoma of mature T cells. These tumor cells home to and persist in the skin,producing a broad spectrum of clinical entities. Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches. Several clinical trials testing these targeted therapies have shown encouraging results. This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
Abstractejd.2011.1564 Auteur(s) : Aristoteles Rosmaninho1 [email protected], Madalena Sanches1, Rosario Alves1,2, Margarida Lima2,3, Manuela Selores1 1 Department of Dermatology 2 Multidisciplinary Consultation for Cutaneous Lymphomas 3 Department of Hematology, Centro Hospitalar do Porto, Rua D. Manuel II, 4099-001 Porto, Portugal Primary cutaneous peripheral T-cell lymphoma, unspecified (PTLU) represents a rare and heterogeneous group of lymphomas. A CD8+ T-cell phenotype is found in a minority [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
